|
Diarrhoea predominant irritable bowel syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, colonization with Clostridia-rich IBS-D fecal microbiota or C. scindens individually enhanced serum C4 and hepatic conjugated BAs but reduced ileal FGF19 expression in mice.
|
31815740 |
2020 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of importance, FGF19 showed higher sensitivity for the detection of small HCC (solitary cancer with diameter < 20 mm) than those of existing markers.
|
31718608 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of importance, FGF19 showed higher sensitivity for the detection of small HCC (solitary cancer with diameter < 20 mm) than those of existing markers.
|
31718608 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Of importance, FGF19 showed higher sensitivity for the detection of small HCC (solitary cancer with diameter < 20 mm) than those of existing markers.
|
31718608 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, it remains to be defined the mechanism through which the FGF19 receptor system is associated with liver damage in NAFLD.
|
31655133 |
2020 |
|
Colorectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The relationship of the GI microbiome, FGF19 and its carcinogenic activities in colorectal neoplasms enticed us to search for potential targets and research ideas for the clinical diagnosis and treatment of colorectal neoplasms.
|
31637718 |
2020 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that increased concentrations of FGF19 and FGF21 in patients with CKD may be associated with the metabolism of lipids and carbohydrates.
|
31614355 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection.<i>See related commentary by Subbiah and Pal, p. 1646</i>.<i>This article is highlighted in the In This Issue feature, p. 1631</i>.
|
31575541 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SIGNIFICANCE: Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC.
|
31575541 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression.
|
31575540 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression.
|
31575540 |
2019 |
|
Hepatocarcinogenesis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on FGFR4 has not been demonstrated.
|
31575540 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes.
|
31572498 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CONCLUSION: We defined a FGF19-SOX18-FGFR4 positive feedback loop that played a pivotal role in HCC metastasis, and targeting this pathway may be a promising therapeutic option for the clinical management of HCC.
|
31529503 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
SOX18 knockdown significantly reduced FGF19-enhanced HCC invasion and metastasis.
|
31529503 |
2019 |
|
Constipation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The new approaches to therapy include ion exchangers/transporters for functional constipation (sodium-glucose cotransporter 1, Na<sup>+</sup>/H<sup>+</sup> exchanger 3, and solute carrier family 26 member 3 inhibitors), bile acid modulators for constipation such as ileal bile acid transporter inhibitors and fibroblast growth factor 19 analog for functional constipation, and bile acid sequestrants or farnesoid X receptor agonists for functional diarrhea.
|
31460793 |
2019 |
|
Constipation - functional
|
0.010 |
Biomarker
|
disease |
BEFREE |
The new approaches to therapy include ion exchangers/transporters for functional constipation (sodium-glucose cotransporter 1, Na<sup>+</sup>/H<sup>+</sup> exchanger 3, and solute carrier family 26 member 3 inhibitors), bile acid modulators for constipation such as ileal bile acid transporter inhibitors and fibroblast growth factor 19 analog for functional constipation, and bile acid sequestrants or farnesoid X receptor agonists for functional diarrhea.
|
31460793 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with lean NAFLD had higher serum secondary BA and FGF19 levels and reduced 7-alpha-hydroxy-4-cholesten-3-one (C4) levels (P < 0.05 for all).
|
31442319 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF401 has remarkable antitumor activity in mice bearing HCC tumor xenografts and patient-derived xenograft models that are positive for FGF19, FGFR4, and KLB.
|
31409633 |
2019 |
|
Malignant neoplasm of liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Childhood Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effect on tumor growth was investigated in 10 different liver cancer models <i>in vivo</i> The antibody specifically slowed tumor growth of models overexpressing FGF19 by up to 90% whereas tumor growth of models not expressing FGF19 was unaffected.
|
31350344 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of both fasting and postprandial plasma BA compositions after oral glucose tolerance test (OGTT), fasting FGF19 and various metabolic indices were measured 1 day before and at 3 days and 3 months after GBP and SG in 19 obese patients (GBP = 8, SG = 11) with T2DM.
|
31273649 |
2019 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance with its murine homolog FGF15, FGF19 might trigger relaxation and filling of the gallbladder which, in combination with increased cholesterol saturation and BA hydrophobicity, would enhance the risk of gallstone development.
|
31254596 |
2019 |